Back to top

Analyst Blog

Over the recent past Life Technologies has been focusing on expanding its diagnostics portfolio. To achieve this objective, the company strengthened its portfolio with the launch of Pervenio Lung RS, a risk stratification test for early stage lung cancer. This 14-gene panel test has been developed by Pinpoint Genomics, which Life Technologies acquired in July, 2012.

This test will provide immense help to a huge patient base by identifying lung cancer patients, who are at a high risk for mortality following surgery,in the early stages. In addition, the test will also aid prevention and disease management.

With a survival tenure of only 5 years for almost 50% of the early stage patients, the identification for patients at high-risk becomes crucial. This is significant as these patients have approximately 25-65% chances of dying even after a successful surgery as the disease often spreads early. It is estimated that the early stage molecular test market is around $120 million in the US and $500 million globally.

Life Technologies also acquired Navigenics in July that has brought in an established, CLIA-certified laboratory licensed throughout the US. This facility will be employed for design and validation of new diagnostic assays.

Earlier this month, Life Technologies entered into a Master Development Agreement with Bristol-Myers Squibb (BMY - Analyst Report) for companion diagnostic projects. The collaboration with Bristol-Myers is in line with the company’s strategy to build partnerships with pharmaceutical majors for companion diagnostic development including participation in early-phase clinical trials. Other partnerships include those with GlaxoSmithKline (GSK - Analyst Report) for MAGE-A3 cancer immunotherapy and with Gen-Probe, which was recently acquired by Hologic (HOLX - Analyst Report).

Life Technologies enjoys a strong position in the life sciences market. We are optimistic about the company’s focus on its diagnostics franchise, which holds potential. However, economic uncertainties in Europe and unfavorable currency were the major headwinds for the company during the last reported quarter.

We have a Neutral recommendation on Life Technologies. The stock carries a Zacks #3 Rank (‘Hold’) in the short term.

Please login to Zacks.com or register to post a comment.

New to Zacks?

Start Here

Zacks Investment Research

Close

Are you a new Zacks Member or a visitor to Zacks.com?

Top Zacks Features

My Portfolio Tracker

Is it Time to Sell?

One of the most important steps you can take today is to set up your portfolio tracker on Zacks.com. Once you do, you'll be notified of major events affecting your stocks and/or funds with daily email alerts.

More Zacks Resources

Zacks Rank Home - Evaluate your stocks and use the Zacks Rank to eliminate the losers and keep the winners.

Mutual Fund Rank Home - Evaluate your funds with the Mutual Fund Rank for both your personal and retirement funds.

Stock/Mutual Fund Screening - Find better stocks and mutual funds. The ones most likely to beat the market and provide a positive return.

My Portfolio - Track your Portfolio and find out where your stocks/mutual funds stack up with the Zacks Rank.

Zacks #1 Rank Top Movers for Zacks #1 Rank Top Movers

Company Symbol Price %Chg
ERBA DIAGNO… ERB 2.99 +2.75%
CHINA BIOLO… CBPO 46.95 +1.92%
CHIPOTLE ME… CMG 689.38 +1.62%
NN INC NNBR 28.43 +1.46%
INTEL CP INTC 34.86 +1.04%